New ZOSTAVAX commercial will
heighten awareness of Shingles vaccine

Be prepared for patient enquiries

I'd like to receive the following (tick all that apply)
Resources to discuss Shingles with my patients
Printed copy of How to Treat Shingles article
Be contacted by my MSD representative

Please complete your personal details if you have selected any of the options above and click submit

I agree to receive information from MSD.
Information may include updates on education, services, events and products provided by MSD (please note some material may be promotional in nature)
I understand that I may unsubscribe from these emails at any time
*I have read and accept the privacy statement below

Privacy Statement: Merck Sharp & Dohme (New Zealand) Limited (MSD) will collect and record your personal information for the purposes of providing you with information about Merck Sharp & Dohme products and activities. We may also use your personal information for the purposes set out in MSD's Notice of Data Practices to Health Care Professionals. We will only disclose your personal information in accordance with MSD's Notice of Data Practices. We will keep your personal information for only as long as is necessary to carry out the purposes described above (unless we are required or permitted by law to hold the information for a longer period). If you would like to know more about our privacy policies and procedures, or if you would like to access or update your personal information, please contact our Privacy Officer at MSD, PO Box 99851, Newmarket, Auckland

THINGS TO KNOW BEFORE USING ZOSTAVAX (zoster virus vaccine, live)
19,400 PFU as 0.65 mL vial for injection:
Indications: for immunisation of individuals 50 years of age or older for the prevention of herpes zoster (shingles), the prevention of postherpetic neuralgia (PHN) and the reduction of acute and chronic zoster-associated pain. Contraindications: patients who are hypersensitive or allergic to any vaccine component including gelatin or neomycin; have a primary or acquired immunodeficiency state or condition; are receiving immunosuppressive therapy; have untreated tuberculosis; are or may potentially be pregnant. Pregnancy should be avoided for 3 months following vaccination. ZOSTAVAX is not recommended for paediatric use, nursing mothers, or those with a fever, epinephrine should be available in case of anaphylactic reaction. Common side effects are: headache, localised injection site reactions and pain in the arm or leg. ZOSTAVAX is a private purchase prescription only medicine that the patient will need to pay for. For detailed prescribing information, consult the data sheet, phone 0800 500 673 or refer to the Medsafe website www.medsafe.govt.nz . Based on data sheet prepared 18/06/2014 Supplied by: Merck Sharp & Dohme (NZ) Limited, Newmarket, Auckland. VACC-1112213-0013. First Issued March 2014. TAPS DA1521MW WEL433887 03/15

Please read our Privacy Policy to learn more about how Merck protects personal information about you. Copyright © 2009 - 2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. VACC-1112213-0013

All rights reserved.